The future of clinical research is increasingly digital, yet France remains cautious when it comes to adopting decentralized clinical trials (DCT). While decentralized clinical trials promise improved patient convenience, faster recruitment, and broader access to innovation, many French sponsors still face regulatory constraints and cultural barriers.
Between the promise of innovation and the realities of implementation, what is really slowing down the adoption of decentralized clinical trials in France?
Decentralized Clinical Trials: Regulatory Challenges and Feasibility in France
To understand why adoption remains limited, it is important to examine decentralized clinical trials through the lens of French regulations.
Unlike the United States, France has traditionally relied on a highly centralized clinical research model built around investigators and hospital-based research centers.
Implementing a decentralized clinical trial or a hybrid study often means moving certain study procedures outside the hospital environment. In France, DCTs are supervised by the ANSM and Ethics Committees (CPPs). Although regulators are increasingly open to innovation, several challenges remain.
Home Healthcare Professional Qualification
Using community nurses for protocol-specific procedures requires dedicated training in Good Clinical Practice (GCP). This additional requirement increases operational complexity.
Health Data Traceability
The GDPR framework and French Health Data Hosting (HDS) requirements create strict obligations when connected devices, wearable technologies, or mobile applications are used in patients’ homes.
Investigator Responsibility
The Principal Investigator remains legally responsible for patient safety throughout the study, even when visits occur remotely. This liability concern continues to discourage some investigators from embracing decentralized clinical trials.
The Missed Opportunity of Home-Based Clinical Research
The greatest strength of decentralized clinical trials lies in hybrid study models that combine site visits with home-based care.
However, many French sponsors still hesitate to move beyond traditional site-centric approaches.
One major challenge concerns investigational product distribution. Delivering temperature-sensitive investigational medicinal products directly to patients requires highly controlled logistics and often raises regulatory questions.
Another challenge involves connected medical devices and wearable technologies. Continuous glucose monitoring systems, wearable ECGs, and remote patient monitoring tools generate vast amounts of data.
Sponsors often worry about data quality, patient compliance, and the potential increase in data variability compared with traditional site-based assessments.
What French Sponsors Still Hesitate to Do
Despite growing European acceptance of decentralized clinical trials, many French sponsors remain cautious about three key innovations.
1. Fully Electronic Informed Consent (eConsent)
Electronic informed consent is much more than a digital signature.
Modern eConsent platforms provide educational videos, interactive content, and personalized learning pathways that can improve patient understanding.
Although some sponsors still fear ethics committee concerns, regulatory authorities are increasingly supportive of eConsent when patient comprehension is adequately demonstrated.
2. Mobile Nursing Services
Using mobile nursing networks for blood sampling, infusions, and patient assessments at home can significantly reduce the burden of participation.
While sponsors sometimes focus on the additional operational costs, studies consistently show that mobile nursing services can improve patient retention and reduce dropout rates in decentralized clinical trials.
Sponsors wishing to monitor the evolution of European standards for decentralized clinical trials can refer to the guidance published by the European Medicines Agency (EMA), which is progressively harmonizing DCT practices across Europe.
3. Remote Collection of Primary Endpoints
Many sponsors are comfortable using wearable technologies for exploratory or secondary endpoints.
However, using connected devices to collect primary endpoints remains relatively uncommon.
Advances in digital health technologies and data science now make it possible to validate remote measurements with a level of accuracy comparable to traditional clinical assessments.
How to Successfully Implement Decentralized Clinical Trials in France
Transitioning toward decentralized clinical trials requires more than simply digitizing existing processes.
Success depends on designing genuinely patient-centric studies from the earliest stages of protocol development.
The guiding principle is simple:
A successful decentralized clinical trial gives patients the flexibility to choose between on-site visits and home-based visits whenever possible.
Key implementation steps include:
Conduct Early Regulatory Risk Assessments
Regulatory experts should be involved during protocol development to identify potential compliance challenges before study initiation.
Select Certified eClinical Solutions
Sponsors should deploy validated eClinical technologies, including:
- Electronic Data Capture (EDC)
- Electronic Patient-Reported Outcomes (ePRO)
- Electronic Clinical Outcome Assessments (eCOA)
These solutions must comply with GDPR, CNIL requirements, and applicable health data regulations.
Detailed information regarding GDPR compliance and health data protection requirements can be found on the website of the French Data Protection Authority (CNIL).
Train Investigators and Clinical Research Associates
Investigators and Clinical Research Associates (CRAs) need dedicated training in telemedicine tools, remote monitoring processes, and digital patient engagement strategies.
Building confidence in remote oversight is essential for successful implementation of decentralized clinical trials.
The Future of Clinical Research Will Be Hybrid
Decentralized clinical trials will not replace hospitals or research centers. Instead, they will transform the way clinical research is conducted.
Sponsors who successfully integrate connected technologies, home healthcare services, electronic consent, and remote patient monitoring into their development strategies will gain a significant competitive advantage.
The benefits are clear:
- Faster patient recruitment
- Improved patient retention
- Better participant experience
- Increased access to real-world data
- More inclusive clinical research
The regulatory environment is evolving, the technology is available, and patients are increasingly ready to participate in flexible research models.
The question is no longer whether decentralized clinical trials will become mainstream in France, but which sponsors will be the first to fully embrace them.
